Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lecanemab Filed for Approval in South Korea: Eisai/Biogen
June 9, 2023
- Astellas Grabs Rights to Kate’s XLMTM Gene Therapy
June 9, 2023
- Opdivo Top-Seller Drug in Japan for 17 Months on End: Encise
June 8, 2023
- Japan Ethical Drug Sales Up 1.4% in April: Crecon
June 8, 2023
- Enhertu Nets Favorable Data in Pan-Tumor Trial for HER2 Solid Cancers
June 7, 2023
- Positive PIb Data Unveiled for TROP2 ADC Plus Keytruda: Daiichi Sankyo/AZ
June 7, 2023
- Mounjaro, Dayvigo Again Top Sales Rep Promotion Rankings for GPs, HPs in April
June 7, 2023
- Japan Firms Joining Fray in siRNA Drug Development; Takeda Could File as Early as FY2025
June 6, 2023
- Japan Approves 1st Gene Panel Testing for IRD
June 6, 2023
- Xocova Given to Over 50,000 Patients in 6 Months: Shionogi
June 6, 2023
- Pfizer Japan Seeks Lupus Nephritis Nod for Rituxan Biosimilar
June 6, 2023
- Kaken, Dong-Wha Ink License Pact for Ecclock in South Korea
June 6, 2023
- Gilead Files HIV Med Lenacapavir in Japan
June 5, 2023
- Women Exec Ratio 14.7% among TSE Prime Drug Makers, Wholesalers; Astellas Leads the Way at 30%
June 2, 2023
- CSL Behring Launches App to Manage HAE Records
June 2, 2023
- Japan Pharma Market Grows for 2 Years Running with 2.6% Rise in FY2022: IQVIA
June 2, 2023
- Shionogi Shoots for Doubling Revenue to 800 Billion Yen by FY2030
June 2, 2023
- Ferring Japan Recalling Fertility Drug Lutinus after Bacteria Detection
June 2, 2023
- Shionogi to End Crestor Sales, AstraZeneca to Go Solo
June 2, 2023
- Pharma Companies in Japan Raising Retirement Age, Extending Rehiring: Jiho Poll
June 1, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…